2016-07-05 14:06:30 UTC

Hydrazine Shows Potential as Therapy for Acute Alcoholic Liver Disease

July 5, 2016

New from CMGH: hydrazine protected mice from the damaging effects of alcohol.

Liver disease is caused by many disorders and toxic agents, of which alcohol is the most common. However, the underlying cellular processes that cause widespread damage, which can lead to cirrhosis, are not well defined.

In a Cellular and Molecular Gastroenterology and Hepatology (CMGH) article in press, Wei-Yang Chen and colleagues demonstrate that acrolein — a byproduct of alcohol consumption that is increased with increased dietary intake of polyunsaturated fatty acids — mediates many of the damaging effects of alcohol on the liver. Hydrazine — an acrolein scavenger in clinical use — protected mice from the damaging effects of alcohol, suggesting that hydralazine or similar drugs might be potential therapies in acute alcoholic liver disease.

For additional insights, read the full, open-access study on the CMGH website: Acrolein Is a Pathogenic Mediator of Alcoholic Liver Disease and the Scavenger Hydralazine Is Protective in Mice.

More on Autoimmune Hepatitis Liver Disease

Member Benefit Spotlight: GastroSlides

June 15, 2017

Free access to AGA's GastroSlides is now a member benefit.

2017-18 AGA GI Resource Catalog

May 30, 2017

Whether it’s the latest in clinical education, cutting-edge science or navigating the future of medicine, AGA has you covered. Find resources to address all of your professional needs in the GI Resource Catalog.

Digestive Disease Week® (DDW)

May 6, 2017

Digestive Disease Week® (DDW) is the premier meeting for the GI professional. Every year it attracts approximately 15,000 physicians, researchers and academics from around the world who desire to stay up-to-date in the field.